isovitexin has been researched along with Cancer of Liver in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, J; Cao, X; Li, X; Liu, L; Ning, Y; Qiu, Y; Ren, K; Xu, C; Zhou, L | 1 |
| Lv, SX; Qiao, X | 1 |
| Cao, J; Cao, X; Chen, A; Chen, X; Cui, Y; Li, X; Liu, L; Qiu, Y; Quan, M; Ren, K; Xu, C; Yuan, Q; Zhang, J; Zou, C | 1 |
3 other study(ies) available for isovitexin and Cancer of Liver
| Article | Year |
|---|---|
Isovitexin Inhibits Stemness and Induces Apoptosis in Hepatocellular Carcinoma SK-Hep-1 Spheroids by Upregulating miR-34a Expression.
Topics: Antineoplastic Agents; Apigenin; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; MicroRNAs; Molecular Structure; Structure-Activity Relationship; Tumor Cells, Cultured; Up-Regulation | 2020 |
Isovitexin (IV) induces apoptosis and autophagy in liver cancer cells through endoplasmic reticulum stress.
Topics: Antineoplastic Agents; Apigenin; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Dose-Response Relationship, Drug; Endoplasmic Reticulum Stress; Hep G2 Cells; Humans; Liver Neoplasms; Mitochondria, Liver; Mitochondrial Proteins | 2018 |
Isovitexin reduces carcinogenicity and stemness in hepatic carcinoma stem-like cells by modulating MnSOD and FoxM1.
Topics: Animals; Apigenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Neoplastic Stem Cells; Promoter Regions, Genetic; Superoxide Dismutase; Xenograft Model Antitumor Assays | 2019 |